Motley Fool Hidden Gems Investing
Chip Outlook Gets Cloudier
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Early is not always better.
(00:21) Jason Moser and Mary Long discuss the semiconductor supply chain, ASML earnings, and what’s ailing the pharmacy industry.
Then, (16:40) Motley Fool contributor Brian Orelli joins for a look at how the genetic testing company 23andme went from a $6 billion valuation to a penny stock in a mere three years … and where the company (and its data) might go from here.
Vote for Motley Fool Money in the 2024 Signal Awards for Best Money and Finance podcast: https://vote.signalaward.com/PublicVoting#/2024/shows/general/money-finance
Learn more about the Range Rover Sport at www.landroverusa.com
Companies discussed: ASML, WBA, CVS, ME, GSK
Host: Mary Long
Guests: Jason Moser, Brian Orelli
Producer: Ricky Mulvey
Engineers: Tim Sparks, Rick Engdahl
Learn more about your ad choices. Visit megaphone.fm/adchoices